retatrutide peptide obesity triple hormone receptor agonist Medscape | Retatrutide, Eli Lilly's first-in-class agonist, delivered meaningful weight loss at 80 weeks in all doses in the Dual and Triple Gut Peptide

Even if youre paying out of pocket, you have some low-cost options to choose from

Nucleic Acids Res 36(Database issue):9016 Wolfsdorf J, Craig ME, Daneman D, Dunger D, Edge J, Lee W et al (2009) Diabetic ketoacidosis in children and adolescents with diabetes

CMS.gov *These statements have not been evaluated by the Food and Drug Administration

There is minimal downtime, allowing you to continue with your daily activities

PlexusDx sources all medications from licensed compounding facilities, ensuring pharmaceutical quality without requiring FDA approval of the compounded formulation itself

In the 2022 SURMOUNT-1 study published in NEJM, three doses of tirzepatide were compared with placebo (1:1:1:1) to determine effects on percent weight change over the course of 72 weeks